ArticleAntimicrobial agents and chemotherapy2019
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 94 citations in OpenAlex.
- Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.The Journal of infectious diseases · 2025Trial
- Article
- Emerging Ocular Pathogen Resistance and Clinically Used Solutions: A Problem That Is More than Meets the Eye.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A novel strategy for the management of cytomegalovirus retinitis in immunocompromised patients using new anti-cytomegalovirus drugs.Frontiers in medicine · 2025Article
- CMV Retinitis in the Context of SARS-CoV-2 Infection: A Case Study and Comprehensive Review of Viral Interactions.Pathogens (Basel, Switzerland) · 2024Review
- Cytomegalovirus chronic retinal necrosis with ganciclovir resistance: a case report.Journal of ophthalmic inflammation and infection · 2024Article
- Review
- Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.Infectious disease reports · 2024Review
- Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.Drug design, development and therapy · 2024Review
- Antiviral therapy defiant mixed viral retinitis post hematopoietic allogeneic stem cell transplant.Clinical case reports · 2023Article
- New Treatment Options for Refractory/Resistant CMV Infection.Transplant international : official journal of the European Society for Organ Transplantation · 2023Review
- Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing.Antiviral research · 2022Article
- Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Microbiology spectrum · 2022Article
- Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022Article
- 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?International journal of molecular sciences · 2022Review
- Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus.Therapeutics and clinical risk management · 2022Review
- Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.Clinical transplantation · 2021Article
- Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.BMC infectious diseases · 2021Article
- Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under cytomegalovirus antigenemia-guided active screening.Bone marrow transplantation · 2021Article
- Commentary: Caveats in the screening and management of cytomegalovirus retinitis in human immune deficiency virus and non-human immune deficiency virus infected patients.Indian journal of ophthalmology · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.